CD38 and Miyoshi myopathy: Daratumumab, an anti‐CD38 fully humanized IgGκ monoclonal antibody, is highly effective for MM treatment and also as a first‐line approach for eligible and ineligible patients to autologous stem cell transplantation (ASCT) [4].